Action Novo Nordisk In Euro: Complete Guide For Investing In 2025

Investing in Novo Nordisk shares in euros constitutes a sought-after strategy by many investors looking to expose themselves to the global pharmaceutical and biotech sectors. With the growth of the diabetes and obesity treatment markets, the Danish company continues to attract the attention of analysts and individuals. This comprehensive guide analyzes Novo Nordisk’s euro-denominated shares in 2025 from all angles: financial context, performance indicators, risks, investment strategies, innovation, and medium-to-long-term prospects. Whether your goal is wealth accumulation, sectoral diversification, or speculation, this report allows you to better understand why Novo Nordisk remains a benchmark value on European and global markets this year.

Presentation Of Novo Nordisk: A Global Leader In Health

Novo Nordisk is a Danish company founded in 1923, internationally recognized for its expertise in researching, developing, and producing innovative treatments primarily for diabetes, obesity, hemophilia, and other rare diseases. Thanks to nearly 100 years of craftsmanship and an innovation culture, Novo Nordisk ranks among the world leaders in the pharmaceutical industry.

The company has approximately 45,000 employees in over 170 countries, marketing its solutions to millions of patients. Novo Nordisk continues to rely on its global network and massive investments in clinical research to develop new treatments, particularly in the field of metabolic and cardiovascular diseases.

Foundation and Governance

Founded in Copenhagen in 1923 by August Krogh and Erling Jørgensen, Novo Nordisk has continuously strengthened its position through solid organic growth and targeted acquisitions. In 2025, the company is preparing for a major overhaul of its board of directors, with the replacement of more than half of its members, including its chairman Helge Lund at the November general assembly. This governance reform aims to accelerate the strategic transformation of the group in the face of growing international competition.

Strategic Positioning And Stock Market

Novo Nordisk's stock is mainly listed on the Copenhagen Stock Exchange under the symbol NVO. It is also accessible to international investors through ADRs (American Depositary Receipts) on the NYSE and other major platforms.

Novo Nordisk's market capitalization remains one of the highest in the European pharmaceutical industry, bolstered by persistent demand for its main treatments and an attractive R&D portfolio. The company leads sector indices and is included in numerous ETFs and global index funds.

Complete Analysis Of Novo Nordisk Shares In Euro

Understanding the valuation, volatility, and potential of Novo Nordisk shares in 2025 requires analyzing the latest financial data and sector trends.

Financial Results 2025: Key Figures To Note

  • Revenue Q3 2025: 74.98 billion Danish crowns, approximately 10 billion euros for the third quarter alone.
  • Revenue for first nine months of 2025: 229.9 billion DKK, close to 30.7 billion euros over the January-September period.
  • Net income Q3 2025: 20.01 billion DKK, approximately 2.7 to 2.8 billion euros, down 27% year-over-year primarily due to restructuring costs.
  • Net income for first nine months of 2025: 75.5 billion DKK, approximately 10.1 billion euros, up compared to the previous fiscal year despite a slowdown in pace.
  • Expected sales growth for 2025: new range set between 8% and 11% (vs. 8–14% previously).
  • Expected operational profit growth: between 4% and 7% (vs. 4–10% initially).
  • Layoff plan announced in 2025: approximately 9,000 positions affected worldwide.
  • Shareholder return: distribution of approximately 53 billion DKK via dividends and share buybacks over the first nine months.

Stock Performance in 2025

After reaching peaks between 2020 and 2024, Novo Nordisk’s stock experienced a marked decline of almost 51% since the beginning of 2025, driven by the combined effects of slowed growth, reduced operating margins, and massive structural reorganization. Despite this correction, the stock remains consistently followed by long-term investors due to the strength of its fundamentals and its portfolio of products in monopoly positions across several global segments of diabetes and obesity.

Historical and Technical Analysis

Over the past five years, Novo Nordisk has demonstrated remarkable resilience against global economic headwinds. While performance was particularly impressive during the 2020–2024 period, the sharp correction at the start of 2025 reminds us that even defensive stocks are not immune to market cycles and sector realignments.

  • 50-day moving average: below the 200-day moving average, illustrating the current downward trend.
  • 200-day moving average: higher indicative value, indicating a deep and prolonged market correction.
  • Average daily volume: increased during periods of high volatility, confirming an intensification of short-term trading on the stock.

Tech indicators show strong volatility since early 2025, a direct consequence of the revised outlook, margin contraction, and restructuring plans. There remains, however, significant interest in the stock thanks to its structural profitability and innovation capabilities.

Strengths and Limitations of Novo Nordisk in 2025

  • Leadership in the diabetes and obesity segments: Novo Nordisk continues to hold a dominant share in these indications thanks to its flagship drugs and investments in R&D.
  • High operating margin: Even after restructuring, the operating margin for the first nine months of 2025 reaches 41.7% (compared to 44.7% in the previous year), demonstrating an efficient business model.
  • Innovation capability: Planned launch of new treatments, particularly in the oral obesity segment (Wegovy Pill), a key asset for the future.
  • Major risks in 2025: Increasing resistance from competitors (especially Eli Lilly), occasional limitations on production capacity, and increased regulatory pressures in the US and Europe.
  • Global transformation plan: Elimination of 9,000 positions and reorganization to gain operational efficiency and achieve expected savings of 8 billion DKK annually by 2026.
  • Dependence on innovation: A significant portion of future growth depends on the commercial success of new products and maintaining technological leadership.

Investment Strategies in Novo Nordisk Shares in Euros

Investing in Novo Nordisk can be done according to several strategies adapted to your profile and investment horizon:

Long-Term Investment

  • Valuation based on the company's robust financial performance, its dominant market position in diabetes and obesity, and its track record of creating value for shareholders.
  • Expectation of a gradual recovery after the early 2025 correction, thanks to the launch of new drugs and its advanced portfolio of innovative treatments.
  • Reinvestment of dividends to maximize the compounding effect over time.

Short-Term/Swing Trading Strategy

  • Speculation on the volatility of the stock following quarterly earnings announcements, target revisions, or regulatory news.
  • Requires expertise in technical analysis and daily monitoring of sector and economic news impacting global health.
  • High risk, potential for rapid losses in the absence of stop-loss controls and price level management.

Indirect Exposure Through Funds and ETFs

  • Investment through mutual funds (MF) or sector-specific Health/Pharma ETFs, integrating Novo Nordisk into their basket of European or global stocks.
  • Reduction of risk through diversification while benefiting from the growth potential of Novo Nordisk.
  • An effective solution for cautious profiles seeking a modulated exposure to the healthcare sector.

Optimization of Fiscal and Euro Investments

  • Purchase of shares through a platform allowing euro purchases, limiting exchange rate risk compared to direct purchase in Danish kroner.
  • Option to place in a PEA-PME according to authorized French envelopes, or through multi-currency brokerage accounts to optimize capital gains tax.

Risks and Precautions Before Investing

If Novo Nordisk attracts many investors, certain points of concern must be taken into account:

  • Regulatory Risks: Legislative changes, increased pressure on drug prices, adoption of stricter health standards.
  • Risk Concentration: Dependence on the success of a few key molecules that make up the bulk of revenue.
  • Increase in Raw Material Costs: Global healthcare inflation and unfavorable exchange rates may impact operational profitability.
  • Sectoral Risks: Expected intensification of international competition, particularly in the obesity segment with the arrival of new players and innovative therapeutic alternatives.
  • One-Time Losses: Decline in net profit in Q3 2025, direct consequences of the restructuring program, may persist in 2026.

Growth Prospects and Strategic Innovations

Novo Nordisk looks to the future by strengthening its commitment to innovation and its ability to respond to growing global metabolic health needs.

  • Continued Growth Through New Treatments: Expected launch of Wegovy in pill form (Wegovy Pill) for obesity, reinforced positioning in cardiovascular treatments, and entry into other metabolic disorders.
  • R&D Investments: Continued increase in research budgets aimed at maintaining technological leadership and expanding the pipeline of new molecules.
  • Geographic Diversification: Acceleration in emerging markets with an access and education strategy to reach wider populations.
  • Digital Transformation: Adoption of digital solutions for patient support, operational efficiency, and integrated clinical trial management.
  • Environmental and Social Goals: Commitment to reducing the carbon footprint of the group and improving access to care in low- and middle-income countries.

Financial Management and Outlook 2025–2026

After a dynamic first half, Novo Nordisk’s 2025 guidance maintains a forecast of sales growth between 8 and 11%, and operating income growth between 4 and 7%, at constant exchange rates. The company expects a gradual recovery in net profitability following internal restructuring and cost rationalization.

Thanks to its recurring profitability, Novo Nordisk is committed to continuing value distribution to shareholders – through generous dividends and share buybacks – while continuing to invest in its main growth drivers (especially in obesity, a segment expected to experience very strong growth in the medium term).

Conclusion: Should One Invest in Novo Nordisk Shares in Euros in 2025?

Despite a severe price correction in 2025 and major operational challenges, Novo Nordisk remains one of the leading pharmaceutical companies globally. Its leadership in major diabetes and obesity markets, innovative pipeline, and prudent financial management provide a solid foundation for potential rebounds in the stock market.

Investing in Novo Nordisk in euros allows for portfolio diversification with a defensive, innovative value that has unique growth drivers on a global scale. As always, it is essential to properly assess sectoral, geopolitical, and short-term volatility risks before any commitment. An investment horizon of several years is recommended to maximize the potential valuation of the stock in a sector where innovation and strategic agility are more important than ever.

FAQ – Frequently Asked Questions About Novo Nordisk Shares in Euros

  • Is Novo Nordisk's stock available in euros? Yes, through certain brokers offering conversion or on platforms allowing the purchase of European stocks.
  • What are Novo Nordisk’s flagship products in 2025? Treatments for diabetes (including Ozempic, Tresiba), Wegovy for obesity, and medications for hemophilia.
  • What are the main risks to watch out for? Intensified competition, changes in regulations, supply chain disruptions, and risks related to the success of innovations.
  • Does Novo Nordisk pay dividends? Yes, its dividend policy remains attractive with a significant portion of profits distributed annually.
  • Mid-term outlook for the stock? A gradual recovery of growth is expected, driven by innovation and increasing global demand in metabolic and cardiovascular segments.